Basildon, UK, 1st December 2013 – Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce that it has completed the acquisition of UK based Marlborough Pharmaceuticals Limited, Huntley Pharmaceuticals Limited and Alphashow Ltd.
The acquisition is the first for Atnahs and is part of a strategic plan to build a global speciality pharma company which focuses on niche established branded and generic medicines. Under the terms of the purchase, Atnahs has acquired the rights to a number of branded medicines including Welldorm® for the treatment of severe insomnia, Sinepin® for the treatment of depression and Dermacort® for the treatment of skin irritations and mild to moderate eczema.
“The acquisition of this range of therapeutic medicines is an exciting time for Atnahs, “said Vijay Patel, founder and co-chairman. “It is the first of a number of strategic acquisitions that we are focusing on as we build on our history and expertise to grow Atnahs into a leading global speciality pharmaceutical company.”
Atnahs is a family owned pharmaceutical business, created by the management team which established, developed and sold Amdipharm Plc to Cinven in November 2012 for £367m.
Atnahs’ Management Team is leveraging its depth of experience and heritage to create a new platform for growth. International acquisitions of niche established branded medicines coupled with a pipeline of niche generic medicines developed in our own facility form the core of our strategy.
Atnahs is based in Basildon, Copenhagen, Vadodara and Sydney.
Contact: Amit Patel at email@example.com or +44(0)1268 594777